NexgenRx Inc.
NXG.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.02M | 2.72M | 2.94M | 2.87M | 3.01M |
| Total Other Revenue | 146.90K | 97.10K | 105.10K | 110.60K | 108.40K |
| Total Revenue | 3.17M | 2.81M | 3.05M | 2.99M | 3.12M |
| Cost of Revenue | 645.70K | 405.20K | 727.60K | 660.80K | 597.10K |
| Gross Profit | 2.53M | 2.41M | 2.32M | 2.32M | 2.52M |
| SG&A Expenses | 1.92M | 1.85M | 1.97M | 2.03M | 1.93M |
| Depreciation & Amortization | 218.80K | 225.60K | 227.10K | 235.50K | 236.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.79M | 2.48M | 2.93M | 2.92M | 2.77M |
| Operating Income | 383.10K | 332.50K | 123.00K | 61.80K | 355.70K |
| Income Before Tax | 351.40K | 323.70K | 92.70K | 6.60K | 324.90K |
| Income Tax Expenses | -15.90K | 343.40K | -16.80K | -16.70K | -17.00K |
| Earnings from Continuing Operations | 367.30K | -19.70K | 109.40K | 23.30K | 341.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 367.30K | -19.70K | 109.40K | 23.30K | 341.90K |
| EBIT | 383.10K | 332.50K | 123.00K | 61.80K | 355.70K |
| EBITDA | 580.10K | 369.70K | 350.10K | 297.30K | 592.10K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 71.12M | 70.47M | 71.08M | 70.92M | 70.92M |
| Average Diluted Shares Outstanding | 76.72M | 70.47M | 76.68M | 76.52M | 72.72M |
| Dividend Per Share | -- | 0.00 | 0.00 | 0.00 | -- |
| Payout Ratio | 6.26% | -370.20% | 22.11% | 1,214.16% | 7.16% |